Experimental cell therapy takes on Hard-to-Treat cancers
NCT ID NCT04898543
First seen Jan 07, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This early-stage study tests a new treatment using a person's own immune cells, called M-CENK, combined with a booster drug (N-803) for advanced solid tumors that have spread. About 50 adults with either newly diagnosed or previously treated cancers will receive the therapy to see if it is safe and shows signs of shrinking tumors. The goal is to find a better option for people with limited choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chan Soon-Shiong Institute for Medicine
El Segundo, California, 90245, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
Conditions
Explore the condition pages connected to this study.